Global licence provides access to InforSense integrative analytics technology across all AstraZeneca research and development (R and D) sites
InforSense reports that AstraZeneca has strengthened its strategic commitment to InforSense technology across its research and development organisation through a new multi-year global licencing deal.
Scientists at AstraZeneca R and D sites will use InforSense's workflow-based integrative analytics environment, InforSense KDE, to derive research intelligence and enhance productivity in their core drug discovery programmes.
InforSense technology has been used at AstraZeneca since 2001.
Following successful pilot installations, the global licencing agreement expands access to InforSense KDE across its R and D organisation for integrative biology, chemistry and text mining applications.
The agreement also includes professional services by InforSense to enable AstraZeneca to leverage its existing discovery software investments within InforSense KDE workflows.
"InforSense is delighted to expand our ongoing collaboration with AstraZeneca," commented Joseph Donahue, chief business officer of InforSense.
"One of the major competitive discriminators between pharma R and D pipelines will be the speed and effectiveness by which they integrate both external and internal data, as well as software tools, within and across domains.
"InforSense technology will enable AstraZeneca to provide such integration across its entire organisation to leverage its knowledge of biology and chemistry research in new ways".
"We have recognised the potential value of InforSense integrative analytics technology at AstraZeneca for effective research decision-making over recent years," said Martyn Wilkins, director of discovery informatics portfolio at AstraZeneca.
"By expanding our commitment to InforSense KDE, we will empower more scientists across our organisation to effectively use information-driven analytics to inform and accelerate their research."
